SMARCA4 and lung cancer: Overall, combinatorial drug screening revealed that pharmacological inhibition with KD025, a ROCK inhibitor, was our most promising therapeutic with IACS-10759 was highly synergistic in all three SMARCA4-mutant lung cancer cell lines (Fig. 1D, Supplementary Fig. 3B-E).